Medtronic's Amplia, Compia MR-conditional cardiac resynchronisation therapy defibrillators gain FDA approval
Top Story
By: Katie Bell
Ref: Medtronic
Published: 02/05/2016
Medtronic announced Friday that it received FDA approval for its Amplia MRI Quad CRT-D SureScan and Compia MRI Quad CRT-D SureScan systems, which the company said are the "first and only" MRI conditional cardiac resynchronisation therapy defibrillators (CRT-Ds) for the treatment of heart failure. The systems, which are approved for MRI scans on any part of the body without positioning restrictions, will be "commercially available in the coming months," Medtronic added.
According to Medtronic, the systems feature quadripolar technology, which optimises CRT delivery, while the Amplia MRI device features the AdaptivCRT algorithm that has been shown to reduce the chance of a heart failure hospital readmission, improve CRT response rate and to reduce atrial fibrillation risk. The device maker added that both devices can be paired with the Attain Perfoma MRI SureScan quadripolar leads.
According to Medtronic, the systems feature quadripolar technology, which optimises CRT delivery, while the Amplia MRI device features the AdaptivCRT algorithm that has been shown to reduce the chance of a heart failure hospital readmission, improve CRT response rate and to reduce atrial fibrillation risk. The device maker added that both devices can be paired with the Attain Perfoma MRI SureScan quadripolar leads.